EP300 and breast cancer: Among them, p300/CBP seems to be frequently mutated in BC (Duex et al., 2018a) and was reported to be associated with doxorubicin resistance (Takeuchi et al., 2012), so it could be a promising molecular therapeutic target for this disease.